Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis

Ki vehet részt

• Age 18 years or older
• Diagnosis of relapsing-remitting multiple sclerosis according to the 2017 McDonald criteria
• At least one gadolinium-enhancing lesion on an MRI of the brain, cervical spine, or thoracic spine within 4 weeks of relapse or hospitalization
• Age 18 years or older
• Able and willing to provide written informed consent and undergo study blood draws
• No diagnosis or history of multiple sclerosis, clinically isolated syndrome, or another inflammatory or demyelinating disorder of the central nervous system
• In generally good health, as determined by medical history and investigator review

Ki nem vehet részt

• Contraindication to or intolerance of oral or intravenous corticosteroids
• Treatment with an anti-CD20 or other B-cell-depleting therapy within 6 months before enrollment
• Active hepatitis B
• Allergy to gadolinium contrast or known allergy to ocrelizumab
• Another known neurological disorder, including a history of progressive multifocal leukoencephalopathy
• Active bacterial, viral, fungal, or mycobacterial infection, or a history of recurrent aspiration pneumonia requiring antibiotic treatment
• A condition that may require chronic systemic corticosteroids or immunosuppressants during the study
• Active cancer or malignancy
• Multiple sclerosis, clinically isolated syndrome, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), or another neurological disorder that may affect study results
• An autoimmune, inflammatory, hematologic, or immunodeficiency disorder that may affect B- or T-cell measurements
• Active bacterial, viral, fungal, or mycobacterial infection at enrollment or blood collection
• Current use of a disease-modifying therapy, B-cell-depleting therapy, systemic immunosuppressant, immunomodulatory therapy, or chronic systemic corticosteroids
• Active cancer or malignancy, except adequately treated localized skin cancer if permitted by the investigator
• A medical condition that, in the investigator's judgment, could increase risk, interfere with participation, or affect interpretation of immune cell or biomarker results
• Diagnosis of primary progressive multiple sclerosis
• Current pregnancy
• Unable to complete an MRI
• Prisoner status
• Limited English-speaking capacity
• Unable to provide informed consent; Healthy Control Participants
• Current pregnancy
• Unable or unwilling to undergo blood collection
• Prisoner status
• Limited English-speaking capacity
• Unable to provide informed consent

Egyéb feltételek

• Participants With Relapsing Multiple Sclerosis (Rapid-Start and Delayed-Start Cohorts)